Accueil>>Signaling Pathways>> Others>> Xenobiotic Sensing>>SPA70

SPA70 (Synonyms: Specific PXR Antagonist 70)

Catalog No.GC49281

SPA70 est un antagoniste puissant et sélectif du récepteur humain du prégnane X (hPXR), avec une IC50 de 540 nM (Ki = 390 nM). SPA70 peut améliorer la chimiosensibilité des cellules cancéreuses.

Products are for research use only. Not for human use. We do not sell to patients.

SPA70 Chemical Structure

Cas No.: 931314-31-7

Taille Prix Stock Qté
1 mg
43,00 $US
En stock
5 mg
194,00 $US
En stock
10 mg
342,00 $US
En stock
25 mg
750,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

SPA70 is a pregnane X receptor (PXR) antagonist (IC50 = 0.51 µM).1 It is selective for PXR over 10 additional nuclear receptors at concentrations greater than 5 µM, as well as over a panel of 384 kinases at 10 µM. SPA70 (0.1-10 µM) inhibits PXR activation induced by rifampicin in HEK293 cells expressing the human receptor. It also inhibits rifampicin-induced activity of the PXR target cytochrome P450 (CYP) isoform 3A4 (CYP3A4) in primary human hepatocytes. SPA70 (200 mg/kg) inhibits PXR agonist-induced CYP3A4-mediated metabolism of midazolam and paclitaxel in human PXR transgenic (hPXR-tg) mice.

1.Lin, W., Wang, Y.-M., Chai, S.C., et al.SPA70 is a potent antagonist of human pregnane X receptorNat. Commun.8(1)741(2017)

Avis

Review for SPA70

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SPA70

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.